Health Care

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Health Care Recent News

Elon Musk's Neuralink Gets Green Light To Launch Brain Chip Trial In Canada: 'Recruitment Is Now Open'
Elon Musk's Neuralink has received Health Canada's approval to conduct its first clinical trial at Toronto Western Hospital, marking its expansion into Canada and opening recruitment for patients with quadriplegia.
FDA Approves Cannabis Trial For Veterans With PTSD After Years Of Delays
FDA approves Phase 2 cannabis trial for veterans with PTSD, funded by Michigan marijuana taxes. Study to assess smoked cannabis efficacy.
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
QuidelOrtho's secondary offering of 8.26 million shares is priced at $38.58, removing an investor overhang, according to William Blair's analysis.
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.
Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis
Quantum-Si partners with NVIDIA to advance AI-powered proteomics, collaborates with Avantor for U.S. and Canada distribution of protein sequencing tech.
Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator
President-elect Donald Trump on Tuesday said that he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS).
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The future remains uncertain.
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved